Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

Primary biliary cirrhosis, known as primary biliary cholangitis is achronic liver disease, which causes liver inflammation, fibrosis, andobstruction in the bile duct leading to destruction of small bileducts within liver. Cause for primary biliary cirrhosis can beautoimmunity, infection and/or genetic predisposition. Symptoms ofprimary biliary cirrhosis includes itching, osteoporosis, elevatedserum cholesterol, and malabsorption of fat and fat soluble vitamins,which can advance to hepatomegaly, hyperpigmentation, splenomegaly,jaundice, sicca syndrome or Kayser-Fleischer rings. 

Primary biliarycirrhosis develops over time and may cause the liver to stop workingcompletely in later stages. Most people are diagnosed early, beforethe disease progresses. Delay in treatment of cirrhosis can causeliver failure and a liver transplant is necessary for survival.Diagnostic tests for primary biliary cirrhosis includes examinationof elevated levels of IgM immunoglobulin levels, lipids, cholesteroland bilirubin, liver biopsy, ultrasonography, CT scanning or MRI.Increasing research and development activities and rising incidenceof primary biliary cirrhosis is expected to be a major driver forgrowth of the PrimaryBiliary Cirrhosis Drugs Market.

Primary BiliaryCirrhosis Drugs Market – Driver

Currently, only two FDA approved drugs, Ursodeoxycholic acid andOcaliva, are available in market to reduce cirrhosis progression.However, large number of drugs are in clinical trials and this isexpected to propel growth of the primary biliary cirrhosis drugmarket in the near future. For instance, in 2017, NGMBiopharmaceuticals, Inc. completed phase II clinical trials for itscandidate drug NGM 282, an engineered variant of human hormone FGF19,to eliminate bile acid toxicity in primary biliary cirrhosispatients. NGM282 has a unique opportunity to leverage the dualtargets of FGF19 without the potential non-tumorigenic property.

Read More@https://bit.ly/3DAL6Io

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe